Gut microbiota and PFS in chemo-immunotherapy for SCLC
47 stool samples from adult patients with extensive-stage small cell lung cancer, collected before and after chemotherapy combined with immunotherapy, comparing long versus short progression-free survival groups. machine-written summary
47 samples · 47 runs · CN · Age unknown · 2025 · 7.92 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 94 sample values (collection date, country) |
| ○ Abstract / description | read; no usable statement |
| ✓ Full text | 141 sample values (antibiotic exposure, health condition, health condition detail) · PMC12992022 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
No Sandpiper profile for this project's samples yet.
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 47 | 100% | ||||
| country | 47 | 100% | 47 | |||
| health_condition | 47 | 100% | 47 | |||
| subject_id | 0 | 0% | ||||
| antibiotic_exposure | 47 | 100% | 47 | |||
| collection_date | 47 | 100% | 47 | |||
| health_condition_detail | 47 | 100% | 47 |
- Correlation between gut microbiota and their metabolites and the efficacy of chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer. 2025 PMID 41853758 PMC12992022 cites_accession
Archive description
Gut microbiota has been reported to be associated with the host's immune system and immunotherapy response, as well as immune-related adverse events (irAEs). Additionally, gut microbial metabolites have various immunomodulatory effects. Our study focused on the differences in gut microbiota and their metabolites between long progression-free survival (PFS) and short PFS in patients with small cell lung cancer before and after chemotherapy combined with immunotherapy. The enrolled patients collected in our department were divided into long PFS and short PFS groups according to whether the PFS was greater than or equal to 6 months, and the stool samples before and after treatment were analyzed using metagenomics and metabolomics. The results showed that Streptococcus (P = 0.00648), Actinomyces (P = 0.0124), and Roseburia (P = 0.0127) differed between the long and short PFS groups. In the analysis of differential metabolites, we found that indirubin-3'-monoxime (AUC 0.611), stearidonic acid (AUC 0.867), leukotriene B4 (AUC 0.844), trans-cinnamic acid (AUC 0.792), and L-tyrosine (AUC 0.751) could be used as potential biomarkers.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by sonnet_x2 with confidence 0.80. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- body site study.description · “stool samples before and after treatment”
- life stage study.description · “patients with small cell lung cancer”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN54235251 | antibiotic_exposure | no | R3 | 0.70 | paper.fulltext.methods | receiving antibiotic treatment within the past 3 months |
| SAMN54235251 | collection_date | 2021-05-01 | R1 | 0.85 | biosample.attribute:collection_date | 2021-05-01 |
| SAMN54235251 | country | CN | R1 | 0.85 | biosample.attribute:geo_loc_name | China:Dalian |
| SAMN54235251 | health_condition | other_cancer | R3 | 0.70 | paper.fulltext.methods | cytological or pathological diagnosis of SCLC |
| SAMN54235251 | health_condition_detail | extensive-stage small cell lung cancer (ES-SCLC) patients treated with chemotherapy plus immunotherapy | R3 | 0.70 | paper.fulltext.methods | cytological or pathological diagnosis of SCLC |
Sequencing
47 runs over 47 samples · mean 7.83 Gbp per run (median 7.92 Gbp, total 368.23 Gbp; 47 runs with a base count) · layout PAIRED 47 · platform ILLUMINA 47 · models Illumina NovaSeq 6000 (47) · 0% of runs with a Sandpiper profile · first public 2025-12-25
Authors (0)
No author record.
Downloads
PRJNA1391873.csv.gz (2.1 KB) · parquet (71.0 KB) — all 47 samples, every field with route and confidence · PRJNA1391873_determinations.csv.gz (2.0 KB) — 235 evidence rows